文献速递心脑血管急症消化、代谢与肾脏急症

老年HIV合并心房颤动患者口服抗凝药的出血风险比较

Comparative Bleeding Risk in Older Patients With HIV and Atrial Fibrillation Receiving Oral Anticoagulants.
PubMed 文献 · JAMA Intern Med · 2025-01-01
一句话结论在HIV合并心房颤动患者中,华法林和利伐沙班较阿哌沙班与更高的住院大出血率相关,尤其在接受抗逆转录病毒治疗者中。

该研究采用目标试验模拟框架,基于美国Medicare索赔数据库(2013年1月1日至2020年12月31日),纳入50岁及以上非瓣膜性心房颤动合并HIV的新使用口服抗凝药患者,比较华法林与阿哌沙班、利伐沙班与阿哌沙班、利伐沙班与华法林的出血风险。经倾向评分重叠加权后,华法林较阿哌沙班大出血风险更高(HR 2.60,95%CI 1.51-4.49),利伐沙班较阿哌沙班亦更高(HR 2.15,95%CI 1.18-3.94),在接受抗逆转录病毒治疗者中关联更强。三种口服抗凝药在缺血性卒中或死亡率方面无显著差异。作者认为阿哌沙班在该高危人群中可能具有更优的安全性。

要点

  • 在HIV合并心房颤动患者中,华法林较阿哌沙班与更高的住院大出血率相关(HR 2.60,95%CI 1.51-4.49)。
  • 利伐沙班较阿哌沙班也与更高的住院大出血率相关(HR 2.15,95%CI 1.18-3.94)。
  • 在接受抗逆转录病毒治疗的71%患者中,华法林vs阿哌沙班的大出血HR为6.68(95%CI 2.78-16.02)。
  • 三种口服抗凝药在缺血性卒中或死亡率方面无显著差异。
  • 作者认为,在HIV合并心房颤动的高危人群中,阿哌沙班可能具有更优的安全性。

适用人群与场景

  • 美国Medicare索赔数据库(2013年1月1日至2020年12月31日)中50岁及以上、非瓣膜性心房颤动合并HIV的新使用口服抗凝药患者。
  • 华法林vs阿哌沙班队列2683人(平均[SD]年龄66.22[8.97]岁;女性580人[21.6%])。
  • 利伐沙班vs阿哌沙班队列2176人(平均[SD]年龄66.61[8.87]岁;女性455人[20.9%])。
  • 利伐沙班vs华法林队列1787人(平均年龄65.47岁;女性377人[21.1%])。

研究设计与关键结果

  • 研究设计:新使用者、活性对照、倾向评分重叠加权的队列研究,采用目标试验模拟框架,分析于2023年7月至2024年4月进行。
  • 主要结局为住院大出血;次要结局包括住院胃肠道出血、缺血性卒中及全因死亡。
  • 华法林vs阿哌沙班:大出血HR 2.60(95%CI 1.51-4.49),大出血性胃肠道出血HR 2.99(95%CI 1.52-5.90)。
  • 在接受抗逆转录病毒治疗的71%患者中,华法林vs阿哌沙班:大出血HR 6.68(95%CI 2.78-16.02),胃肠道出血HR 5.28(95%CI 2.08-13.42)。
  • 利伐沙班vs阿哌沙班:大出血HR 2.15(95%CI 1.18-3.94),胃肠道出血HR 3.38(95%CI 1.57-7.25)。
  • 在接受抗逆转录病毒治疗者中,利伐沙班vs阿哌沙班:大出血HR 4.83(95%CI 2.11-11.08),胃肠道出血HR 4.76(95%CI 1.78-12.70)。
  • 利伐沙班vs华法林的估计值相似。
  • 三种口服抗凝药在缺血性卒中或死亡率方面无显著差异。

证据类型、等级与局限

  • 证据类型:基于美国Medicare索赔数据库的新使用者、活性对照、倾向评分重叠加权队列研究(目标试验模拟框架)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在HIV合并心房颤动患者中,尤其是接受抗逆转录病毒治疗者,华法林和利伐沙班较阿哌沙班与更高的住院大出血率相关,提示阿哌沙班在该高危人群中可能具有更优的安全性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: People living with HIV and atrial fibrillation (AF) often receive anticoagulation that may interact with their antiretroviral therapy (ART). No studies exist comparing the safety of oral anticoagulants in this population.

OBJECTIVE: To compare the bleeding risks among warfarin, rivaroxaban, and apixaban users in a national US cohort with AF and HIV.

DESIGN, SETTING, AND PARTICIPANTS: A new-user, active-comparator, propensity score overlap-weighted cohort study using the target trial emulation framework including Medicare claims database data (January 1, 2013, to December 31, 2020) was carried out. The analysis was conducted from July 2023 to April 2024.

EXPOSURE: New initiators of warfarin vs apixaban, rivaroxaban vs apixaban, and rivaroxaban vs warfarin aged 50 years or older with nonvalvular AF and HIV.

MAIN OUTCOMES AND MEASURES: The primary outcome was hospitalization for major bleeding. Secondary outcomes included hospitalization for gastrointestinal bleeding, ischemic stroke, and all-cause mortality.

RESULTS: Overall, 2683 individuals (mean [SD] age, 66.22 [8.97] years; 580 female individuals [21.6%]) in the warfarin vs apixaban cohort, 2176 (mean [SD] age, 66.61 [8.87] years; 455 female individuals [20.9%]) in the rivaroxaban vs apixaban cohort, and 1787 (mean age, 65.47 years; 377 female individuals [21.1%]) in the rivaroxaban vs warfarin cohort. After propensity score overlap weighting, warfarin initiation was associated with a higher rate of major bleeding than initiation of apixaban (hazard ratio [HR], 2.60; 95% CI, 1.51-4.49), including major gastrointestinal bleeding (HR, 2.99; 95% CI, 1.52-5.90). This association was intensified in the 71% of patients taking concurrent ART (major bleeding, HR, 6.68; 95% CI, 2.78-16.02; gastrointestinal bleeding, HR, 5.28; 95% CI, 2.08-13.42). Rivaroxaban vs apixaban was also associated with a higher rate of major bleeding (HR, 2.15; 95% CI, 1.18-3.94) and gastrointestinal bleeding (HR, 3.38; 95% CI, 1.57-7.25), with a stronger association in those using ART (major bleeding, HR, 4.83; 95% CI, 2.11-11.08; gastrointestinal bleeding, HR, 4.76; 95% CI, 1.78-12.70). Estimates were similar when comparing rivaroxaban with warfarin. No significant difference was observed in the rate of ischemic stroke or mortality among the 3 oral anticoagulants.

CONCLUSIONS AND RELEVANCE: This study found that in patients with HIV and AF, especially those treated with ART, warfarin and rivaroxaban were associated with higher rates of major bleeding compared with apixaban, suggesting a superior safety profile for apixaban in this high-risk population.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Quinlan CM, Avorn J, Kesselheim AS, et al. Comparative Bleeding Risk in Older Patients With HIV and Atrial Fibrillation Receiving Oral Anticoagulants. JAMA Intern Med. 2025. PMID: 39992678. doi:10.1001/jamainternmed.2024.8335

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。